TX-MARY-KAY
22.12.2022 17:06:37 CET | Business Wire | Press release
Mary Kay recently announced its sustainability strategy – Enriching Lives Today for a Sustainable Tomorrow – which encompasses five pillars, 15 commitments, and over a decade of action. This strategy was developed with Mary Kay’s key stakeholders and is aligned with the United Nations’ Sustainable Development Goals, making Mary Kay an essential part of a global coalition to ensure a better future.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221222005031/en/
Mary Kay Inc. partners with local and global organizations to further their mission to enrich women’s lives and bring education opportunities to young women around the world.
As part of this overarching strategy and to continue its decades-long advocacy for women’s empowerment, education and entrepreneurship, Mary Kay is committed to providing 250,000 young women education opportunities by 2030. To further its mission of enriching women’s lives, partnerships and scholarships with local and global organizations in 2022 ensured young women around the world are provided with exceptional education opportunities to pursue their dreams.
2022 Mary Kay Inc. Partnerships/Programs included:
- Young Women in STEAM Grants – Six recipients received grants created to elevate young women in STEAM fields and encourage them to continue their passions and career pursuits. The 2022 recipients were from N. Macedonia, Germany, the Philippines, China, and Australia pursuing careers in everything from app development and architecture to physics and geothermal inventions.
- Young Women in STEAM Continuing Education Grant – As an extension of Mary Kay’s Young Women in STEAM grants and social campaign, Ivanna Hernandez, a 2021 grant recipient, was awarded a second grant to help further pursue her dream of becoming the first Latin American woman astronaut to go to Mars. She was featured in a documentary created to inspire young women to shoot for the stars – or Mars in this case!
- Society of Cosmetic Chemists Madam C. J. Walker Scholarship – Established to honor Walker, the first female, self-made millionaire who made her fortune by developing a line of cosmetics and hair care products for Black women. At the SCC 75th Annual meeting, Ms. A’Lelia Bundles, the great-great-granddaughter of Madam C.J. Walker, and Michelle Hines, Ph.D., Director of Product Formulation at Mary Kay, presented the Madam C. J. Walker Scholarships for under-represented minority students pursuing higher education in STEM disciplines related to the cosmetics and personal care industry. The award is supported by the Society of Cosmetic Chemists and partnered and funded by Mary Kay. The winning recipients included: Joy Rutherford, fifth-year PhD student and NIH Research Fellow; and Imani Elaine Porter, Hampton University, second-year undergraduate in biochemistry.
- Network for Teaching Entrepreneurship – Partnering to provide 47,000 youth globally with entrepreneurship curriculum and innovative thinking opportunities. Through support of 1) the Aspiring Entrepreneurs Program (U.S.) core program; 2) World Series of Innovation; and 3) World Series of Innovation Challenge Innovation Days, Mary Kay is helping to empower youth to reach their entrepreneurial dreams. In the 2021-2022 school year, Mary Kay sponsored the NFTE World Series of Innovation (WSI) where 21 teams of emerging social entrepreneurs won a total of $16,800 for their proposed solutions to seven challenges, each of which focused on advancing a Sustainable Development Goal. Sponsors of the seven innovation challenges included: Bank of the West, Citi Foundation, Mary Kay, Saint-Gobain North America, Ernst & Young, LLP (EY), Maxar Technologies, and PIMCO. The 2022 World Series of Innovation Challenge launched in September 2022 and Mary Kay is participating for a third year tackling SDG 14: Life Below Water.
- City of Lewisville, IncubatorEDU – In partnership with the Lewisville Independent School District (LISD), IncubatorEDU offers a robust entrepreneurship curriculum to Lewisville High School students. Community mentors and an end-of-year pitch event provide the students with real-life entrepreneurial experience and education opportunities.
- Academy of Marketing Science – For more than 25 years, Mary Kay has supported the Mary Kay Dissertation and Dissertation Proposal Awards at the annual Academy of Marketing Science (AMS) conference where doctoral student participants showcase their successfully defended dissertations and receive a monetary award and critical peer feedback to improve their chances of publishing their work in academic journals in the future.
- Ursuline Academy of Dallas – Mary Kay Ash Endowed Scholarship – Scholarship awarded annually to support girls with an education that equips them with the skills and confidence needed to do great things.
- Army Scholarship Foundation - Mary Kay Corporation Honorary Scholarship – Scholarship awarded annually to deserving sons and daughters of US Army soldiers and Army veterans, and to spouses of enlisted active-duty soldiers.
- Hispanic Scholarship Fund – Scholarship awarded annually to support and empower students and parents with the knowledge and resources to successfully complete a higher education, while providing support services and scholarships to as many exceptional students, HSF scholars and Alumni as possible.
About Mary Kay
One of the original glass ceiling breakers, Mary Kay Ash founded her dream beauty company in 1963 with one goal: enriching women’s lives. That dream has blossomed into a multibillion-dollar company with millions of independent sales force members in nearly 40 countries. As an entrepreneurship development company, Mary Kay is committed to empowering women on their journey through education, mentorship, advocacy, networking, and innovation. Mary Kay is dedicated to investing in the science behind beauty and manufacturing cutting-edge skincare, color cosmetics, nutritional supplements, and fragrances. Mary Kay believes in enriching lives today for a sustainable tomorrow, partnering with organizations from around the world focusing on promoting business excellence, supporting cancer research, advancing gender equality, protecting survivors from domestic abuse, beautifying our communities, and encouraging children to follow their dreams. Learn more at marykayglobal.com, find us on Facebook, Instagram, and LinkedIn, or follow us on Twitter.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221222005031/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom